Whalesbook
Granules India's strong financial results for the fourth quarter of fiscal year 2026 have boosted its stock. The performance marks a significant recovery after a slower period from fiscal years 2023 to 2025, driven by strategic product diversification and increased sales in key segments. These positive results have drawn analyst attention, reinforcing confidence in the company's future direction.
Strong Q4 Earnings Drive Performance
Granules India reported substantial growth in its fourth quarter for fiscal year 2026, ending March 31, 2026. Revenue from operations rose approximately 23% year-on-year to ₹14,706 million. Earnings before interest, taxes, depreciation, and amortization (EBITDA) surged 40% year-on-year to ₹3,521 million, with EBITDA margins expanding to 24% from 21% in the prior year. Consolidated net profit increased by 33% year-on-year to ₹2,016 million. For the full fiscal year 2026, revenue grew 20% year-on-year to ₹53,656 million, and net profit rose 19% to ₹5,950 million. The company's stock reacted positively, trading up 2% following the results announcement. Growth in finished dosages (FD) contributed 73% of revenues, alongside Active Pharmaceutical Ingredients (API) at 13%, and the Peptide/CDMO platform at 5%. Geographically, North America accounted for about two-thirds of sales, while Europe showed high momentum with nearly doubled performance.
Valuation and Sector Context
Granules India currently trades with a Trailing Twelve Months (TTM) Price-to-Earnings (P/E) ratio ranging from approximately 28.7 to 44.15. Motilal Oswal reiterated a 'BUY' recommendation with a price target of INR 820, based on a valuation of 21 times 12-month forward earnings. This suggests confidence in continued growth and potential margin improvement. The company operates in the Indian pharmaceutical sector, focusing on API and Finished Dosage Formulations (FDF). The Indian API market is projected to grow 5% to 7% annually through FY28, supported by government policies and a shift towards high-potency and complex APIs. Granules' strategy in complex generics and its Peptide CDMO platform align with these trends. Financially, the company maintains a healthy balance sheet, with a debt-to-equity ratio of approximately 0.35 as of March 2025 and a net debt-to-EBITDA ratio improving to 0.34x in FY26.
Margin Sustainability and Risks
Despite the strong Q4 performance, underlying risks require attention. The recent expansion in EBITDA margins to 24% in Q4 FY26 is a key focus for sustainability. While management attributes this to portfolio expansion and disciplined execution, historical regulatory challenges, including US Food and Drug Administration (USFDA) warnings related to its Gagillapur facility, introduce caution. Investors will watch if margin gains are sustainable or face pressure from increasing competition, potential pricing erosion in generic APIs, or renewed regulatory compliance costs. The company's reliance on complex generics and CDMO necessitates continuous investment and strong execution in a competitive global market. The current high TTM P/E ratio already reflects significant growth expectations, leaving little room for error if execution falters or market conditions change. The move from basic to complex APIs requires sustained R&D and manufacturing expertise, where competitors are also investing heavily.
Future Outlook
Looking ahead, analysts like Emkay Global anticipate fiscal year 2027 growth driven by product launches, with additional controlled drug products expected to support expansion from fiscal year 2028. Granules India's Chairman and Managing Director, Dr. Krishna Prasad Chigurupati, highlighted continued momentum in complex generics and the peptides CDMO platform as key growth drivers. He emphasized disciplined execution and progress in regulatory, compliance, and sustainability initiatives for future success. Strategic investments in facilities, such as the Genome Valley 10 billion dosages facility and its US packing facility, are intended to fuel this next phase of growth.